PEDIATRIX MEDICAL GROUP INC (MD) Fundamental Analysis & Valuation
NYSE:MD • US58502B1061
Current stock price
23.04 USD
+0.28 (+1.23%)
At close:
23.04 USD
0 (0%)
After Hours:
This MD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MD Profitability Analysis
1.1 Basic Checks
- MD had positive earnings in the past year.
- In the past year MD had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
- MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- MD has a Return On Assets of 7.36%. This is amongst the best in the industry. MD outperforms 88.00% of its industry peers.
- MD has a better Return On Equity (19.10%) than 86.00% of its industry peers.
- The Return On Invested Capital of MD (9.88%) is better than 82.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 8.43%.
- The 3 year average ROIC (8.21%) for MD is below the current ROIC(9.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROIC | 9.88% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
1.3 Margins
- MD has a Profit Margin of 8.64%. This is amongst the best in the industry. MD outperforms 92.00% of its industry peers.
- MD's Profit Margin has improved in the last couple of years.
- Looking at the Operating Margin, with a value of 12.07%, MD belongs to the top of the industry, outperforming 85.00% of the companies in the same industry.
- MD's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A |
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. MD Health Analysis
2.1 Basic Checks
- MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, MD has less shares outstanding
- Compared to 5 years ago, MD has less shares outstanding
- The debt/assets ratio for MD has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 2.13 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
- MD has a Altman-Z score (2.13) which is comparable to the rest of the industry.
- The Debt to FCF ratio of MD is 2.36, which is a good value as it means it would take MD, 2.36 years of fcf income to pay off all of its debts.
- MD's Debt to FCF ratio of 2.36 is fine compared to the rest of the industry. MD outperforms 74.00% of its industry peers.
- A Debt/Equity ratio of 0.66 indicates that MD is somewhat dependend on debt financing.
- The Debt to Equity ratio of MD (0.66) is comparable to the rest of the industry.
- Even though the debt/equity ratio score it not favorable for MD, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Altman-Z | 2.13 |
ROIC/WACC1.14
WACC8.63%
2.3 Liquidity
- A Current Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
- With a decent Current ratio value of 1.66, MD is doing good in the industry, outperforming 68.00% of the companies in the same industry.
- MD has a Quick Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD has a better Quick ratio (1.66) than 69.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 |
3. MD Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 36.24% over the past year.
- Measured over the past years, MD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.01% on average per year.
- The Revenue has decreased by -4.92% in the past year.
- Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 1.99% on average per year.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
3.2 Future
- MD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.99% yearly.
- The Revenue is expected to grow by 3.93% on average over the next years.
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. MD Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 11.35, the valuation of MD can be described as very reasonable.
- 90.00% of the companies in the same industry are more expensive than MD, based on the Price/Earnings ratio.
- MD is valuated cheaply when we compare the Price/Earnings ratio to 27.42, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 10.01, which indicates a very decent valuation of MD.
- 90.00% of the companies in the same industry are more expensive than MD, based on the Price/Forward Earnings ratio.
- MD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.35 | ||
| Fwd PE | 10.01 |
4.2 Price Multiples
- MD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MD is cheaper than 84.00% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, MD is valued cheaper than 90.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.58 | ||
| EV/EBITDA | 7.46 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.85
PEG (5Y)1.13
EPS Next 2Y8.67%
EPS Next 3Y4.87%
5. MD Dividend Analysis
5.1 Amount
- No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MD Fundamentals: All Metrics, Ratios and Statistics
23.04
+0.28 (+1.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19 2026-02-19/bmo
Earnings (Next)05-05 2026-05-05/bmo
Inst Owners103.94%
Inst Owner Change2.45%
Ins Owners2.05%
Ins Owner Change-0.8%
Market Cap1.91B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.76 (-5.56%)
Short Float %4.34%
Short Ratio3.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-0.78%
PT rev (3m)-5.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)0%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.35 | ||
| Fwd PE | 10.01 | ||
| P/S | 1 | ||
| P/FCF | 7.58 | ||
| P/OCF | 7.06 | ||
| P/B | 2.21 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.46 |
EPS(TTM)2.03
EY8.81%
EPS(NY)2.3
Fwd EY9.99%
FCF(TTM)3.04
FCFY13.2%
OCF(TTM)3.26
OCFY14.16%
SpS23.04
BVpS10.42
TBVpS-4.96
PEG (NY)0.85
PEG (5Y)1.13
Graham Number21.8192 (-5.3%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROCE | 12.93% | ||
| ROIC | 9.88% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 1686.9% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A | ||
| FCFM | 13.2% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Debt/EBITDA | 2.26 | ||
| Cap/Depr | 84.57% | ||
| Cap/Sales | 0.96% | ||
| Interest Coverage | 6.72 | ||
| Cash Conversion | 107.19% | ||
| Profit Quality | 152.75% | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 2.13 |
F-Score8
WACC8.63%
ROIC/WACC1.14
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.33%
EBIT Next 3Y6.84%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%
PEDIATRIX MEDICAL GROUP INC / MD Fundamental Analysis FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MD.
Can you provide the valuation status for PEDIATRIX MEDICAL GROUP INC?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
Can you provide the profitability details for PEDIATRIX MEDICAL GROUP INC?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.
Can you provide the financial health for MD stock?
The financial health rating of PEDIATRIX MEDICAL GROUP INC (MD) is 6 / 10.